Literature DB >> 17678502

Production of a monoclonal antibody in plants with a humanized N-glycosylation pattern.

Matthias Schähs1, Richard Strasser, Johannes Stadlmann, Renate Kunert, Thomas Rademacher, Herta Steinkellner.   

Abstract

In recent years, plants have become an attractive alternative for the production of recombinant proteins. However, their inability to perform authentic mammalian N-glycosylation may cause limitations for the production of therapeutics. A major concern is the presence of beta1,2-xylose and core alpha1,3-fucose residues on complex N-linked glycans, as these N-glycan epitopes are immunogenic in mammals. In our attempts towards the humanization of plant N-glycans, we have generated an Arabidopsis thaliana knockout line that synthesizes complex N-glycans lacking immunogenic xylose and fucose epitopes. Here, we report the expression of a monoclonal antibody in these glycan-engineered plants that carry a homogeneous mammalian-like complex N-glycan pattern without beta1,2-xylose and core alpha1,3-fucose. Plant and Chinese hamster ovary (CHO)-derived immunoglobulins (IgGs) exhibited no differences in electrophoretic mobility and enzyme-linked immunosorbent specificity assays. Our results demonstrate the feasibility of a knockout strategy for N-glycan engineering of plants towards mammalian-like structures, thus providing a significant improvement in the use of plants as an expression platform.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17678502     DOI: 10.1111/j.1467-7652.2007.00273.x

Source DB:  PubMed          Journal:  Plant Biotechnol J        ISSN: 1467-7644            Impact factor:   9.803


  62 in total

Review 1.  Lepidopteran cells, an alternative for the production of recombinant antibodies?

Authors:  Martine Cérutti; Josée Golay
Journal:  MAbs       Date:  2012-04-26       Impact factor: 5.857

2.  Second-generation HIV microbicides: continued development of griffithsin.

Authors:  Larry Zeitlin; Michael Pauly; Kevin J Whaley
Journal:  Proc Natl Acad Sci U S A       Date:  2009-04-08       Impact factor: 11.205

Review 3.  Emerging antibody products and Nicotiana manufacturing.

Authors:  Kevin J Whaley; Andrew Hiatt; Larry Zeitlin
Journal:  Hum Vaccin       Date:  2011-03-01

4.  NMR-based structural validation of therapeutic antibody produced in Nicotiana benthamiana.

Authors:  Hirokazu Yagi; Noriho Fukuzawa; Yasushi Tasaka; Kouki Matsuo; Ying Zhang; Takumi Yamaguchi; Sachiko Kondo; Shiori Nakazawa; Noritaka Hashii; Nana Kawasaki; Takeshi Matsumura; Koichi Kato
Journal:  Plant Cell Rep       Date:  2015-02-18       Impact factor: 4.570

Review 5.  Current Developments and Future Prospects for Plant-Made Biopharmaceuticals Against Rabies.

Authors:  Sergio Rosales-Mendoza
Journal:  Mol Biotechnol       Date:  2015-10       Impact factor: 2.695

6.  Advances in molecular farming: key technologies, scaled up production and lead targets.

Authors:  Henry Daniell; Stephen J Streatfield; Edward P Rybicki
Journal:  Plant Biotechnol J       Date:  2015-10       Impact factor: 9.803

Review 7.  With or without sugar? (A)glycosylation of therapeutic antibodies.

Authors:  Dmitrij Hristodorov; Rainer Fischer; Lars Linden
Journal:  Mol Biotechnol       Date:  2013-07       Impact factor: 2.695

8.  In planta protein sialylation through overexpression of the respective mammalian pathway.

Authors:  Alexandra Castilho; Richard Strasser; Johannes Stadlmann; Josephine Grass; Jakub Jez; Pia Gattinger; Renate Kunert; Heribert Quendler; Martin Pabst; Renaud Leonard; Friedrich Altmann; Herta Steinkellner
Journal:  J Biol Chem       Date:  2010-03-20       Impact factor: 5.157

9.  Rapid transient production in plants by replicating and non-replicating vectors yields high quality functional anti-HIV antibody.

Authors:  Frank Sainsbury; Markus Sack; Johannes Stadlmann; Heribert Quendler; Rainer Fischer; George P Lomonossoff
Journal:  PLoS One       Date:  2010-11-12       Impact factor: 3.240

Review 10.  Plant-based strategies aimed at expressing HIV antigens and neutralizing antibodies at high levels. Nef as a case study.

Authors:  Carla Marusic; Alessandro Vitale; Emanuela Pedrazzini; Marcello Donini; Lorenzo Frigerio; Ralph Bock; Philip J Dix; Matthew S McCabe; Michele Bellucci; Eugenio Benvenuto
Journal:  Transgenic Res       Date:  2009-01-25       Impact factor: 2.788

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.